Cardiff Oncology Showcases Promising Phase 2 Onvansertib Results Ahead of ASCO 2026
SAN DIEGO, Calif., May 21, 2026 Cardiff Oncology, Inc. announced that updated data from its ongoing Phase 2 CRDF-004...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SAN DIEGO, Calif., May 21, 2026 Cardiff Oncology, Inc. announced that updated data from its ongoing Phase 2 CRDF-004...
